Sign up for ICER's Weekly View Newsletter

 

Weekly View


June 12, 2026

From the desk of Priya Ranade

Good morning, everyone.

ICER published an Evidence Report for Covid-19 vaccines yesterday. The report includes four Covid-19 vaccines: Comirnaty® (Pfizer, BioNTech), Spikevax® (Moderna), mNexspike® (Moderna), and Nuvaxovid® (Sanofi).

 

ICER’s Chief Medical Officer, David Rind, MD, MSc stated:


“Covid-19 infections continue to occur year-round, sometimes leading to serious illness or death. For any preventive care, the goal is always to understand whether the potential benefits outweigh the potential harms. ICER evaluated the evidence for Covid-19 vaccines in 12 US sub-populations. Current evidence suggests that the greatest net benefit of Covid-19 vaccination is in pregnant women; infants aged 6 months to one year; and adults over the age of 65, with the net benefit increasing further with increasing age. Declining rates of serious Covid-19 year over year necessarily create some uncertainties. We hope this report will be a useful resource to policymakers and public health officials as they consider vaccination recommendations for Covid-19 for the 2026-2027 season.”

 

Register here for a June 25th public meeting on Covid-19 vaccines. An independent appraisal committee will review the findings of the ICER Evidence Report, hear further testimony from stakeholders, and deliberate on the clinical effectiveness, benefits beyond health, and long-term value for money.

Let's see what else happened this week...

 

ICER in the News

 

Institute for Clinical and Economic Review Publishes Final Evidence Report on Treatment for Narcolepsy

ICER released a Final Evidence Report on oveporexton for narcolepsy type 1. ICER’s Senior Vice President of Research, Foluso Agboola, MBBS, MPH, stated:

 

“The narcolepsy treatment landscape includes several pricey medications that do not provide complete relief for patients. ICER’s analyses found that oveporexton, the first medication for narcolepsy type 1 that directly addresses the underlying cause of the condition, is effective in promoting wakefulness, improving quality of life, and appears to offer better health benefits than current options. The manufacturer choosing a value-based price for oveporexton would help de-escalate the cycle of high prices being met with onerous access challenges. Our independent analysis can offer a roadmap for improving affordability and access for patients and the health system.”

 
Pharmaceutical News

MUST READS


Emerging State Data Paint a Bleak Picture of 2026 Marketplace Enrollment

The Commonwealth Fund

Congress failed to extend the Affordable Care Act's (ACA) enhanced tax credits at the end of 2025 and, earlier this year, enacted a tax-and-spending law that further reduced federal spending on marketplace coverage and imposed new paperwork burdens.


Federal regulators have so far released data on initial sign-ups during open enrollment, which include people whose coverage was automatically renewed at the end of 2025. However, enrollment is not complete until the first month’s premium is paid. Unprecedented net premium hikes in 2026 have prompted some people who signed up for coverage to drop it — either by canceling their policy or simply not paying their premium. Federal regulators are not expected to release the first snapshot of nationwide paid enrollment data until this summer.

AMA Endorses Drug Pricing Policies, Not Yet Sold On MFN

Inside Health Policy

At the American Medical Association's (AMA) annual House of Delegates meeting this week, the AMA backed several administrative and legislative efforts to lower drug prices. For example, they advocated that cash payments for prescription drugs (made by insured individuals through DTC platforms) must count toward their deductibles. The AMA is not committed to backing international reference pricing efforts like the Trump administration’s “Most Favored Nation” (MFN) policy.

Some US employers to drop coverage of GLP-1 obesity drugs in 2027 as use increases

Reuters

Some employers are planning to drop coverage of GLP-1 drugs for weight loss next year as more people take the medications, counteracting some savings from lower prices for Novo Nordisk's Wegovy and Eli Lilly's Zepbound ​and Foundayo. About 10% of employers who now cover GLP-1 drugs for weight-loss said they planned to drop the ‌drugs in 2027, according to the Business Group on Health, a policy research group for large employers.

Big Pharma lost in court — Congress must not bail it out

The Hill

Merith Basey, the CEO of Patients for Affordable Drugs, recently penned an op-ed on the legal challenges to the Medicare Drug Price Negotiation Program:


"Six drugmakers — AstraZeneca, Boehringer Ingelheim, Bristol Myers Squibb, Janssen, Novartis and Novo Nordisk — asked the Supreme Court to gut Medicare’s authority to negotiate lower drug prices. The court said no, leaving intact a string of lower court defeats and closing every legal avenue for the six companies.


To understand the pharmaceutical industry’s argument, you must understand what it was trying to restore. For more than two decades, Medicare was barred from negotiating lower prescription drug prices for Americans — not because negotiation was unconstitutional, but because the industry wrote that prohibition into law. No other industry has ever claimed such a protection. That meant American patients paid far more for their brand-name medications than patients in other wealthy countries, where governments routinely negotiate prices."

OTHER HEADLINES

 

Join ICER!

 

Want to work for a fast-paced, mission-driven organization? Look no further! ICER is looking to expand our team:



 

Key Upcoming Dates

 
  • 7/27: Parkinson's Disease -- Draft Evidence Report
  • 7/28: Covid-19: Final Evidence Report

Learn more about ICER’s ongoing and recently completed reports:

Email info@icer.org for more information.

When you make a gift to ICER, you help keep ICER independent.  

 
 
 
 
 
LinkedIn Share This Email